Advertisements

Depo-Provera

Quick links to important sections

Depo-Provera

Selected form

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Depo-Provera

Property Description
Active Ingredient Medroxyprogesterone Acetate (MPA)
Form Injectable Suspension (IM or SC)
Pharmacological Class Progestogen
Common Use Long-Acting Reversible Contraception (LARC)
Origin Synthetic Progestin

Depo-Provera is the brand name for a hormonal medication whose active ingredient is medroxyprogesterone acetate (MPA), a synthetic progestin. It is widely recognized as the first quarterly progestin-only injectable contraceptive available on the market, administered as a suspension.

This specific formulation is unique because it provides a sustained, long-acting dose from a single injection, distinguishing it from daily oral pills. The drug is composed of a microcrystalline suspension of medroxyprogesterone acetate in a liquid vehicle, which allows for a slow, steady release over several months.


What is the Pharmacological Class and General Purpose?

Medroxyprogesterone acetate belongs to the progestogen pharmacological class, meaning it acts similarly to the natural hormone progesterone in the body. Its primary therapeutic purpose is for long-acting reversible contraception (LARC), which is intended to provide protection against pregnancy for approximately three months.

Medroxyprogesterone is classified as a progestin, a synthetic derivative of the naturally occurring female hormone progesterone. Aside from contraception, MPA is also licensed for managing conditions like endometriosis and is used as an adjunctive treatment for specific types of hormone-sensitive cancers.


How is Depo-Provera Classified?

Depo-Provera is clinically classified as an injectable contraceptive method and is grouped under hormonal birth control that falls into the LARC category. It requires administration by a healthcare provider every 12 to 14 weeks, making it a convenient option for users seeking to avoid the routine of daily medication.

This quarterly administration schedule is a key differentiating factor, offering a high degree of compliance and effectiveness. Because its function relies on consistent, sustained delivery of the progestin MPA, it is considered one of the user-independent reversible contraceptives available.

Advertisements

What side effects are possible with Depo-Provera?

Possible Side Effects and Safety Information

The official safety profile of medroxyprogesterone acetate (Depo-Provera) is structured by regulatory authorities to classify adverse reactions based on frequency, system involvement, and exposure context.


Frequency and System-Organ Classes

The incidence of adverse effects is officially categorized in regulatory documents. Very Common events (ge 1/10) include menstrual irregularities (such as amenorrhea or unpredictable bleeding), weight increase, headache, and nervousness. Reactions classified as Common (ge 1/100 to <1/10) include dizziness, depression, nausea, acne, and injection site reactions.

Adverse effects are documented across multiple System-Organ Classes, extending beyond the reproductive system to include the Nervous System, Psychiatric Disorders, and Gastrointestinal Disorders.


Serious and Contextual Safety Notes

The regulatory profile lists uncommon but serious adverse reactions such as thromboembolic events (Deep Vein Thrombosis and Pulmonary Embolism). A primary safety concern highlighted by regulatory bodies is the potential for Bone Mineral Density (BMD) loss, which is explicitly associated with long-term use (e.g., use exceeding two years).

Population-Specific Constraints are documented, including warnings regarding BMD loss in adolescents and a contraindication for individuals with severe hepatic dysfunction or disease. Furthermore, the official labeling notes that a delay in the return to fertility may occur after treatment discontinuation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the management of overdosage with medroxyprogesterone acetate (MPA) formulations, focusing on manifestations and mandated emergency actions.

Overdosage may present with systemic manifestations, including nausea, vomiting, breast tenderness, dizziness, abdominal pain, and drowsiness/fatigue, along with withdrawal bleeding. In high-dose scenarios, such as those exceeding 500 mg daily, corticoid-like activity may be observed, potentially leading to signs like blood pressure elevation.

Immediate Medical Attention is Required When: The most critical scenarios involve severe, acute hypersensitivity reactions. The prescribing information mandates seeking emergency medical attention for symptoms suggestive of anaphylaxis or anaphylactoid reactions.

Management of overdosage is strictly limited to supportive measures. There is no specific antidote known for MPA overdosage. Treatment consists solely of discontinuation of therapy (where applicable) together with the institution of appropriate symptomatic care and observation, as the long-acting injectable nature of the drug constrains active removal interventions.

Advertisements

Therapeutic Uses of Depo-Provera

What Depo-Provera Treats: Main Uses and Benefits

The active ingredient in Depo-Provera is used across multiple therapeutic domains. Its primary use is to provide long-acting reversible contraception (LARC), offering continuous protection and pregnancy prevention. This therapeutic feature is considered relevant for women seeking sustained protection over several months, generally supporting long-term reproductive planning.

It is also applied in the management of distressing symptoms related to physical discomfort arising from endometriosis, and is relevant for easing chronic pelvic pain and severe menstrual cramps (dysmenorrhea). It is applied in contexts where patients may experience lighter periods or cessation of bleeding. This feature helps manage heavy menstrual bleeding (menorrhagia) and may assist with maintaining overall functional stability by addressing related issues like systemic imbalance.

Medroxyprogesterone acetate is used as an adjunctive hormonal therapy in the palliative or advanced management of specific malignancies, including certain endometrial, renal, and breast cancers in postmenopausal women. In these contexts, the therapeutic role is to offer supportive management that can contribute to easing the overall symptom load and supports patients during episodes of heightened discomfort.


Quick Fact: Relief for Chronic Pain and Bleeding The medication is relevant for easing challenging symptoms associated with endometriosis, and helps manage heavy or painful periods, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH StatPearls on Medroxyprogesterone
Advertisements

Eligibility and Restrictions for Use

The eligibility for using Depo-Provera (medroxyprogesterone acetate injectable suspension) is strictly governed by regulatory classifications, which define absolute prohibitions and conditional restrictions.

Populations for Whom Use is Contraindicated

The medicine must not be used (is contraindicated) in individuals with specific health conditions or statuses, including:

  • Known or suspected pregnancy or use as a diagnostic test for pregnancy.
  • Active thrombophlebitis or a current/past history of thromboembolic disorders or cerebral vascular disease.
  • Known or suspected malignancy of the breast or other hormone-dependent malignancy.
  • Significant liver disease (severe chronic liver dysfunction).
  • Undiagnosed abnormal uterine bleeding.
  • Known hypersensitivity to medroxyprogesterone acetate or any formulation ingredient.

Age- and Condition-Based Restrictions

Classification Population / Condition Restriction Type
Adolescent Use Females under 18 (post-menarche) Not recommended as a long-term method (longer than 2 years) unless other options are inadequate, due to concerns about bone mineral density (BMD) loss.
Geriatric Use Postmenopausal women Contraceptive use is not indicated.
Lactation Status Exclusively breastfeeding mothers Initiation is generally restricted until at or after the sixth postpartum week.
Metabolic Status Patients with diabetes mellitus Requires careful monitoring due to potential decrease in glucose tolerance.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for medroxyprogesterone acetate (MPA) based on regulatory labeling.


Pharmacokinetic Interaction Profile

Classification Substance Categories
Metabolic Pathway MPA is metabolized primarily by hydroxylation via the CYP3A4 enzyme.
Avoided Combinations Strong CYP3A Inhibitors and Strong CYP3A Inducers.

Official Interaction Statements

The interaction profile for Depo-Provera is predominantly defined by substances that affect the CYP3A4 metabolic pathway, leading to changes in MPA exposure.

  • Strong CYP3A Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) are expected to decrease MPA plasma concentrations. Co-administration with these substances is to be avoided due to the potential reduction in contraceptive efficacy.
  • Strong CYP3A Inhibitors (e.g., ketoconazole, ritonavir) are expected to increase MPA plasma concentrations. Co-administration with these substances is also to be avoided.
  • Aminoglutethimide may significantly depress the serum concentrations of medroxyprogesterone acetate.
  • The herbal product St. John’s Wort is classified as a strong CYP3A inducer and is officially to be avoided.

Official labeling explicitly states that the effect of renal impairment on MPA pharmacokinetics has not been studied, nor have clinical studies evaluated the effect of hepatic disease on MPA disposition.

Advertisements

Mechanism of Action

The action of Depo-Provera (medroxyprogesterone acetate or DMPA) is defined by its effects on the progesterone receptor system, resulting in three layers of biological change that influence reproductive processes at the biological and physiological level.

Central Suppression of the Ovulatory Cascade

DMPA modulates the hypothalamic-pituitary-ovarian (HPO) axis by binding to progestin receptors. This interaction centrally suppresses the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), the essential neuroendocrine mediators for follicular maturation and oocyte release. This mechanistic cascade results in the inhibition of ovulation (anovulation), a key physiological consequence of HPO axis suppression.

Modulation of Peripheral Reproductive Barriers

This secondary domain involves DMPA's local effect on the reproductive tract. The drug alters the consistency of cervical mucus, causing it to become thick and dense, and induces atrophy of the endometrium (uterine lining). These changes create biological barriers that inhibit sperm passage and render the uterine environment less favorable for potential implantation.

Sustained Pharmacologic Activity

The specific microcrystalline formulation of DMPA establishes an intramuscular depot from which the drug is slowly and continuously absorbed over approximately 13 weeks. This sustained-release mechanism maintains stable, systemic concentrations of the progestin, thereby enabling the continuous suppression of the HPO axis and the maintenance of peripheral barriers.

Advertisements

Dosage and Administration Information

Administration Process

Depo-Provera is administered as an intramuscular injection. The procedure is performed by a healthcare professional in a clinical setting. The injection is typically given in the buttock or the upper arm. The site of the injection should not be massaged afterward to ensure the medication is absorbed as intended.

Timing and Schedule

For the medication to be effective, it must be administered at regular intervals. The first injection is usually given during the first five days of a normal menstrual cycle to ensure that pregnancy has not occurred. If the injection is administered at other times during the cycle, additional contraceptive measures may be necessary for a short period.

Subsequent injections are scheduled every 12 to 13 weeks. Maintaining this schedule is necessary for continuous contraceptive protection. If a significant amount of time passes beyond the scheduled date for a follow-up injection, a pregnancy test may be required before the next dose can be administered.

Transitioning from Other Methods

When switching from other forms of contraception, the timing of the first injection depends on the method previously used.

  • Oral Contraceptives: The first injection is typically given within seven days of taking the last active pill.
  • Other Progestin-only Methods: The injection may be administered on the day the previous method is discontinued or the device is removed.
  • Postpartum: For those who are not breastfeeding, the injection may be administered within five days postpartum. If breastfeeding, the timing may be adjusted based on clinical guidance.

Long-Term Use

Use of this medication beyond two years requires an assessment of the benefits and potential effects on bone mineral density. Periodic evaluations are recommended for individuals who continue the treatment over an extended duration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Depo-Provera


Evidence for Use in Long-Acting Contraception (Pregnancy Prevention)

The primary research exploring the use of medroxyprogesterone acetate for contraception was conducted in large-scale Randomized Controlled Trials (RCTs) and Controlled Clinical Studies. These trials evaluated the medication's use in women of reproductive age, including adolescents and adults. Researchers primarily examined outcomes related to contraceptive efficacy measures under both perfect and typical use conditions, physiological changes throughout the dosing period, and medication adherence over time.

Studies describe patterns of physiological changes monitored during the dosing period. Research explored the contraceptive efficacy measures observed in studies where the medication was administered according to the defined injection schedule. Findings describe group patterns, not personal outcomes, and do not determine whether an individual will respond similarly. Evidence is limited regarding the medication's use over many years, as follow-up durations were often limited in many studies.


Evidence for Management of Endometriosis Symptoms

The research base for this use was evaluated in Randomized Controlled Trials and comprehensive Systematic Reviews that included comparative trials against other hormonal treatments. The primary focus of these studies was to explore patient-reported outcomes describing perceived discomfort, specifically changes in physical discomfort related to dysmenorrhea (painful periods) and chronic pelvic pain.

Studies reported patterns in patient-reported pain scores and severity levels observed in the study groups during the treatment period. Comparative trials explored outcomes where physical discomfort was monitored when compared against other active hormonal comparator drugs. Research is ongoing to fully characterize the long-term impact. Evidence quality varies across studies, and data suggest that symptom recurrence after treatment remains a key limitation.


What is Still Uncertain About the Evidence

The current research highlights what is known and what is still uncertain across all indications. For contraception, adherence to the injection schedule was associated with the outcomes observed in real-world settings. For cancer therapy, certainty remains low due to findings that were mixed or non-significant in meta-analyses of survival. Overall, long-term effects are not fully established across all indications, and research does not determine whether an individual will experience patterns similar to those described in the group findings.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Depo-Provera (FAQ)


Q: Is Depo-Provera a type of birth control pill?

According to official product information, Depo-Provera is classified as a long-acting, progestin-only injectable contraceptive. It is administered as a shot by a healthcare professional every three months, distinguishing it from daily oral birth control pills.


Q: How soon after the shot does Depo-Provera start working?

Contraceptive effectiveness is generally established immediately if the initial injection is given within the first five days of a normal menstrual period. If the injection is given at any other time, official guidance recommends using a backup method of birth control, such as condoms, for the first seven days.


Q: Can you stop using Depo-Provera at any time?

The decision to discontinue the medication can be made at any time, but it is important to discuss this with a healthcare professional. Because the drug is a long-acting injection, its effects are not immediately reversible, and the return of a patient's fertility may be delayed for several months after the last dose.


Q: Do you gain weight when using Depo-Provera?

Regulatory documents state that weight increase is a very common adverse reaction reported in clinical trials. Patients often experience an average weight gain that may increase over time with continued use of the drug.


Q: Does Depo-Provera affect bone density over time?

Official labeling contains a warning that the use of Depo-Provera is associated with a loss of bone mineral density (BMD). This loss increases with the duration of use and may not be completely reversible after stopping the drug. Due to this concern, regulatory guidance advises against the use of the drug for longer than two years unless other contraceptive options are considered inadequate.


Q: How long does it take for fertility to return after stopping Depo-Provera?

There is typically a delay in the return to fertility after stopping the injections. Studies indicate that the average time for patients to conceive after the last injection is approximately ten months, but individual variation means this time frame can vary widely.


Q: Does Depo-Provera work differently than the birth control implant (Nexplanon)?

While both the implant and Depo-Provera are progestin-only methods, they differ in administration. Depo-Provera is a quarterly injection, whereas the implant is a small device inserted under the skin that provides contraception for a longer period. Their specific hormone delivery profiles can lead to differences in side effects.


Q: Is it possible to get pregnant while using Depo-Provera correctly?

No contraceptive method is 100% effective. Clinical studies show that with typical use, the pregnancy rate is around 6 pregnancies per 100 women over the first year. Contraceptive effectiveness is maintained by adhering to the required injection schedule.


Q: Does Depo-Provera have a risk of blood clots compared to estrogen-containing methods?

Serious blood clot events have been reported in women using Depo-Provera. However, unlike contraceptives that contain estrogen, the drug has not been causally associated with the induction of thrombotic disorders in the same way.


Q: What happens to the hormone levels in my body after the injection wears off?

The drug is designed to be slowly released from the injection site, maintaining high levels for about 13 weeks. After this period, the concentration of the hormone in the bloodstream declines gradually over time, which accounts for the potential delay in the return of fertility.


Q: Is the Depo-Provera shot painful?

Injection site reactions, which can include temporary mild pain, swelling, or redness at the injection site, are listed as a common adverse reaction in clinical trial data.


Q: What happens if I get the Depo-Provera shot late?

If the time between injections is greater than 13 weeks, the effectiveness of the drug may be compromised. Official guidance specifies that pregnancy must be ruled out by a healthcare professional before the subsequent injection is administered.


Q: Will Depo-Provera affect my mood?

Regulatory information indicates that psychiatric disorders are among the reported adverse reactions. Nervousness is listed as a very common event, and depression is listed as a common event in patients using the drug.


Q: Can Depo-Provera make my periods stop completely?

Changes in bleeding patterns are very common. Amenorrhea, or the complete absence of menstrual bleeding, is frequently reported in clinical studies. The rate of this side effect increases the longer a patient uses the drug.


Q: Is it normal to feel bloated after receiving the Depo-Provera injection?

Abdominal discomfort, which may include feelings of bloating, is listed among the common gastrointestinal adverse reactions reported in regulatory documentation for Depo-Provera.


Q: Does Depo-Provera protect against sexually transmitted infections (STIs)?

No, the official Patient Information Guide explicitly states that Depo-Provera does not provide protection against HIV (AIDS) or any other sexually transmitted infections (STIs).


Q: Is it normal to feel tired or fatigued when on Depo-Provera?

Yes, tiredness and fatigue are listed in the regulatory documents as common adverse reactions reported during clinical trials of the drug.


Q: What part of the body does the Depo-Provera shot go into?

The drug is given either as a deep intramuscular (IM) injection, typically into the gluteal (buttocks) or deltoid (shoulder) muscle, or as a subcutaneous (SC) injection into the anterior thigh or abdomen, depending on the formulation used.


Q: Does Depo-Provera cause changes in breast tenderness?

Yes, regulatory labeling reports that both breast pain and generalized breast tenderness are listed as common adverse reactions experienced by users.


Q: Can Depo-Provera be used by people with a history of migraines?

Official labeling states that patients with a history of migraines should be carefully monitored. The drug’s regulatory labeling advises against re-administration, pending examination, if a new onset of severe migraine or sudden partial or complete loss of vision occurs.


Q: What are the signs that Depo-Provera might not be working for me?

The primary sign that contraceptive efficacy may have failed is the occurrence of pregnancy. If the injection interval is missed or if a patient experiences unusual or heavy bleeding, regulatory guidance specifies that pregnancy should be ruled out by a healthcare professional.


Q: What is the difference between Depo-Provera and progesterone-only pills (mini-pills)?

Both methods contain only a progestin hormone. The difference is the administration schedule: Depo-Provera is a long-acting injection given every three months, whereas mini-pills are oral contraceptives that must be taken every day.


Q: Is there a preferred time in the menstrual cycle to get the first Depo-Provera shot?

Yes, to ensure that the patient is not pregnant, the first injection must be given only within the first five days of a normal menstrual period. A specific post-partum timing is also required if the patient is not breastfeeding.


Q: Why do doctors recommend calcium supplements for Depo-Provera users?

Due to the established risk of bone mineral density (BMD) loss associated with the use of this drug, regulatory information advises on the consumption of adequate calcium and vitamin D, through diet or supplements, and participation in regular weight-bearing exercise to promote skeletal health.


Q: Can I switch directly from another birth control method to Depo-Provera?

Yes, the official labeling provides instructions for switching. For example, when changing from oral contraceptives, the first injection is typically given the day after the last active pill to ensure continuous contraceptive protection.


Q: Is the Depo-Provera injection administered in a specific dosage amount?

Yes, the drug is administered in a fixed amount for contraception (150 mg for IM or 104 mg for SC). The dose is not adjusted based on the patient's body weight.


Q: Are there any specific lifestyle changes needed when using Depo-Provera?

Regulatory documents recommend lifestyle adjustments focused on mitigating the risk of bone mineral density loss. This includes ensuring adequate intake of calcium and Vitamin D and engaging in regular weight-bearing exercise.


Q: Are there any long-term health concerns associated with using Depo-Provera for many years?

The primary long-term health concern noted in the official Boxed Warning is the potential for bone mineral density (BMD) loss. Due to this risk, regulatory guidance advises against using the drug for longer than two years unless other contraceptive methods are considered inadequate.


Q: Does Depo-Provera affect libido or sex drive?

Yes, changes in libido (sex drive), including decreased libido, are listed among the common adverse reactions reported during clinical trials of the drug.

Advertisements

How should Depo-Provera be stored and disposed of?

Official Storage and Disposal Requirements

Depo-Provera (medroxyprogesterone acetate injectable suspension) must be stored strictly according to the conditions stated in the official regulatory labeling.

Storage Conditions

Requirement Specification
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Prohibited Conditions Do not refrigerate and do not freeze the product.
Handling Vials must be stored upright. The suspension must be vigorously shaken just prior to administration.
Protection Keep this medicine and all its components out of the reach of children.

Disposal Instructions

  • Sharps: Used needles and syringes must be disposed of immediately in an approved sharps disposal container.
  • Product: Do not dispose of unused or expired medicine through wastewater or household trash. Official instructions require that environmental release must be avoided due to potential aquatic toxicity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Depo-Provera found in:

A-Z Index: